Navigation Links
Halozyme Therapeutics to Present at Upcoming Investor Conferences
Date:10/22/2008

SAN DIEGO, Oct. 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today announced that it will present at three upcoming investor conferences:

-- BIOCOM Investor Conference to be held at the Hyatt Regency in La Jolla, Calif. on Monday, October 27, 2008 at 2:00 p.m. PDT (5:00 p.m. EDT);

-- Oppenheimer's 19th Annual Healthcare Conference to be held at the Waldorf-Astoria Hotel in New York on Monday, November 3, 2008 at 10:40 a.m. EST (7:40 a.m. PST); and

-- Lazard Capital Markets 5th Annual Healthcare Conference to be held at the St. Regis Hotel in New York on Tuesday, November 18, 2008 at 2:40 p.m. EST (11:40 a.m. PST).

Interested parties can access a live audio webcast and accompanying slides of the conference presentations via the internet by visiting the Investor Relations section of Halozyme's website at http://www.halozyme.com. Archived presentations will be available on the website for 30 days following the presentation dates.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the drug delivery, metabolism, oncology, and dermatology markets. The company's portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter's biological therapeutic product, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. Halozyme also has a number of additional enzymes in its portfolio that target significant areas of unmet medical need. For more information visit http://www.halozyme.com.

Halozyme Contact Media Contacts

Robert H. Uhl Karen Sparks / Joleen Schultz

Senior Director, Investor Relations Mentus

(858) 704-8264 (858) 455-5500, x275/x215

ruhl@halozyme.com karen@mentus.com jschultz@mentus.com


'/>"/>
SOURCE Halozyme Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Halozyme Therapeutics to Host Research Day for Investors and Analysts
2. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
4. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
5. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
6. Halozyme Therapeutics to Present at the Jefferies 2nd Annual Healthcare Conference
7. Halozyme Therapeutics Reports 2008 First Quarter Financial Results
8. Halozyme Therapeutics to Hold Pipeline Update Conference Call on May 9
9. Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results
10. Halozyme Therapeutics Presents Favorable New Safety and Pharmacokinetic Data on rHuPH20 Enzyme Produced Via New Manufacturing Process at European Federation for Pharmaceutical Sciences
11. Halozyme Therapeutics to Hold Pipeline Update Conference Call on March 14
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... and NEW YORK , Feb. ... Lumeon , a leading digital health company, and ... provider of telemedicine and remote patient monitoring, announce ... telemedicine reimbursements.  DN Telehealth maximizes ... in real-time, extending consultations beyond a physical clinical ...
(Date:2/23/2017)... ... 2017 , ... BellBrook Labs is formalizing a significant expansion ... biochemical analyses critical for Lead Discovery. The company’s Lead Discovery Services will ... inhibitor potency and selectivity, mechanism of action, and inhibitor residence times on drug ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... , Feb. 23, 2017  Seattle,s upscale Capitol Hill ... a strange place for a head lice treatment salon to ... between a Tuscan restaurant and a French bistro on E ... perfect. "We aren,t just any old lice clinic, we pride ... feel comfortable, and release some of the stigma associated with ...
Breaking Biology Technology:
(Date:2/7/2017)... Feb. 7, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the LEERINK Partners 6th Annual ... Hotel on Wednesday, February 15, 2017 at 10 a.m. ... the presentation can be accessed at http://wsw.com/webcast/leerink28/zbh .  ... conference via Zimmer Biomet,s Investor Relations website at ...
(Date:2/2/2017)... 2, 2017   TapImmune, Inc. (NASDAQ: ... specializing in the development of innovative peptide and ... cancer and metastatic disease, announced today it has ... of a second clinical lot of TPIV 200, ... alpha. The manufactured vaccine product will be used ...
(Date:1/30/2017)... --  Invitae Corporation (NYSE: NVTA ), ... announced that it will report its fourth quarter and ... Monday, February 13, 2017, and Invitae,s management team will ... Eastern / 1:45 p.m. Pacific. During ... results, guidance, and recent developments and will spend the ...
Breaking Biology News(10 mins):